Comparing Iterum Therapeutics (NASDAQ:ITRM) & Indivior (OTCMKTS:INVVY)

Indivior (OTCMKTS:INVVY) and Iterum Therapeutics (NASDAQ:ITRM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Earnings and Valuation

This table compares Indivior and Iterum Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$791.00 million	3.81	$205.00 million	$1.05	20.81
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04

Indivior has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Indivior and Iterum Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0	0	1	0	3.00
Iterum Therapeutics	1	2	0	0	1.67

Indivior presently has a consensus price target of $50.00, indicating a potential upside of 128.88%. Given Indivior’s stronger consensus rating and higher probable upside, research analysts plainly believe Indivior is more favorable than Iterum Therapeutics.

Profitability

This table compares Indivior and Iterum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	N/A	N/A	N/A
Iterum Therapeutics	N/A	N/A	-65.54%

Institutional and Insider Ownership

0.1% of Indivior shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Indivior has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the S&P 500.

Summary

Indivior beats Iterum Therapeutics on 8 of the 12 factors compared between the two stocks.

About Indivior

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.